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Recreational inhalation of nitrous oxide (N2O) is
under-recognised in the UK, with potentially serious health
risks. Adolescents and young adults presenting with the
neurological complications of repeated N2O use are seen
regularly in east London emergency departments.1 Greater
awareness of this emerging public health problem is needed.
Nitrous oxide is a colourless gas, with minimal odour and
variable taste. Inhalation of N2O can produce a short lived, rapid
onset euphoria and a dissociative effect. This is often
accompanied by spontaneous laughter, hence the colloquial
name “laughing gas.” Historically, N2O was inhaled as a
recreational substance long before its potential use as an
anaesthetic and analgesic agent was recognised.2 Importantly,
N2O is always combined with oxygen in clinical settings to
minimise the risk of hypoxia,3 but it is inhaled neat by
recreational users.
Although the clinical use of N2O in anaesthesia has been
declining in the UK and elsewhere,4 5 its popularity as a
recreational drug has increased among adolescents and young
adults.6 7 The 2017 Global Drug Survey found that it was one
of the 10 most commonly used recreational drugs worldwide
(excluding alcohol, tobacco, and caffeine products).7 In a UK
government survey, 8.8% of young people (aged 16-24) admitted
to using N2O in 2017-18 compared with 6.1% in 2012-13.
6 8
The recreational use of N2O in the UK has persisted despite the
introduction of the Psychoactive Substances Act 2016, which
prohibited the sale of nitrous oxide for recreational
consumption.6 The gas is sold legally for use outside healthcare,
as an engine accelerant in the motor industry and as a propellant
in the production of whipped cream. Small metal whipped cream
chargers (“whippits”) or canisters, each containing 8 g of
compressed gas, are a common source of N2O for recreational
use (fig 1). Boxes of N2O canisters are cheap and easy to buy
from shops, street dealers, and social media or mainstream
websites.6 Pre-filled balloons of N2O can also be purchased.
Nitrous oxide (N2O) canisters (whipped cream chargers).
A “cracker” device is used to pierce N2O canisters and
release the gas into balloons used for inhalation
Short and long term harms
Users of N2O may experience dizziness, vomiting, and fainting
soon after consumption. Inhalation of N2O, particularly in
enclosed environments, can lead to hypoxia and asphyxiation.9 10
Although N2O inhalation is rarely fatal, at least three deaths
have been attributed to N2O in the UK in each of the past five
years, with eight cases in 2016.11
Prolonged exposure to N2O can lead to neurological impairment
from sensorimotor peripheral neuropathy and subacute combined
degeneration of the spinal cord.1 12 13 N2O oxidises the cobalt ion
in vitamin B12 (cobalamin), impairing its function. The
mechanism of subsequent neuronal injury is not known, but one
theory is that cobalamin inactivation reduces the generation of
methionine, which is necessary for the methylation of myelin
sheath proteins.10 12
In 1978, 15 cases of suspected spinal cord degeneration were
reported across the US, all associated with repeated recreational
or occupational N2O exposure, mainly among dentists.
13 Between
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1 November 2016 and 1 May 2017, 10 cases among recreational
users were diagnosed at the Royal London Hospital,1 and at
least 10 more cases were seen the following year.
Patients with peripheral neuropathy or spinal cord degeneration
can present with paraesthesia, numbness, or sensory ataxia.1 12-14
Serum vitamin B12 levels can be low or normal, but raised
methylmalonic acid or homocysteine concentrations indicate a
functional B12 deficiency.
1 12 Patients presenting with
neurological deficits have reported inhaling N2O on average
two to three times a week, and in large quantities (sometimes
more than 100 canisters a day).1 12
We do not know if there is a safe level of N2O use, but
prescribing guidelines exist in the UK to limit the frequency
and duration of patients’ exposure to N2O in clinical settings.
3
Nonetheless, cases have been reported of patients developing
neurological problems after repeated clinical administration of
N2O for analgesia.
12 14 Neurological recovery after N2O cessation
and high dose vitamin B12 replacement is variable.
1 12 14
Prolonged N2O use can also precipitate megaloblastic changes
in the bone marrow,15 although many patients with neurological
symptoms have normal mean corpuscular volume and
haemoglobin levels.1 12 Mood changes, bladder and bowel
disturbance, and erectile dysfunction have also been reported
after habitual N2O use and may be particularly
under-recognised.13
Public education
To reduce harm local authorities must publicise the adverse
effects associated with frequent N2O use and encourage users
with neurological symptoms to seek early medical help. The
No Laughing Matter campaign in the London Borough of Tower
Hamlets is targeting antisocial behaviour and littering associated
with recreational N2O use as well as the illegal sale of N2O.
16 17
Clinical coding and documentation of N2O use and related
symptoms in both primary and secondary care are currently
inconsistent and must be improved. Systematic coding using
either SNOMED CT or ICD-10 will aid patient follow-up,
population health planning, and early detection of symptoms
that may precede serious neurological impairment. Equally
important is further research to better understand the
mechanisms underlying neurological damage linked to N2O and
to quantify any potential dose threshold for harm.
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